ATP Supplementation for COVID-19 ARDS and Hypoxia

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The existing treatments for COVID-19, particularly for patients with respiratory distress and hypoxia, are inadequate, leading to high mortality rates and the need for mechanical ventilation, which can be ineffective and risky, especially for individuals with pre-existing conditions such as cystic fibrosis.

Innovation Solution

Administering adenosine triphosphate (ATP) and adenosine derivatives to increase ATP levels in patients, either orally or intravenously, to alleviate symptoms of COVID-19, including Acute Respiratory Distress Syndrome (ARDS) and hypoxia, by mimicking the beneficial effects of cystic fibrosis, which is associated with elevated ATP levels, thereby reducing the need for ventilators and improving survival rates.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If mechanical ventilation is used to treat respiratory distress and hypoxia in COVID-19 patients, then oxygen levels can be maintained, but the risk of exposure to others increases and the treatment becomes unnatural requiring hospitalization and sedation

Engineering Contradiction:

Improveoxygen maintenanceVSAvoidexposure risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces the mechanical ventilation system with a biochemical treatment approach using ATP supplementation. Instead of mechanically forcing oxygen into the lungs, the invention addresses the underlying energy depletion by administering ATP to restore cellular energy levels, thereby treating the root cause of respiratory failure rather than its mechanical symptoms

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If mechanical ventilation is used to treat respiratory distress, then oxygen uptake can be supported, but the treatment process is unnatural and requires hospitalization

Engineering Contradiction:

Improveoxygen uptake supportVSAvoidtreatment naturalness

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent enables the body's natural energy production systems to restore function by supplementing ATP directly. The treatment allows the patient's own cellular mechanisms to recover and maintain oxygen uptake naturally, rather than imposing an external mechanical system. The body essentially serves itself by utilizing the supplemented ATP to regenerate its energy reserves

Inventive Principle:

Principle #25Self-service

3Productivity

If ventilators are made more available to treat severe COVID-19 cases, then more patients can receive life-saving treatment, but the underlying energy depletion issue remains unaddressed

Engineering Contradiction:

Improvetreatment capacityVSAvoidtreatment effectiveness

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent applies preliminary action by addressing the root cause of respiratory failure (energy depletion) before it progresses to the point where mechanical ventilation becomes necessary. By supplementing ATP early in the disease course, the treatment prevents the development of severe hypoxia and respiratory distress, thereby reducing the need for ventilator intervention altogether

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20250312370A1Systems and methods for use of adenosine triphosphate (ATP) to relieve symptoms of covid-19 and related infections

Publication Date: 2025.10.09 ADENYLATE THERAPEUTICS LLC

AI summary

Treatments for SARS-CoV-2 infection, COVID-19, symptoms of COVID-19, and similar infections. Specifically, treatments for patients identified as having Acute Respiratory Distress Syndrome (ARDS), and specifically COVID-19 ARDS, and/or suffering the effects of hypoxia. The treatments include increasing a patient's naturally occurring levels of ATP, adenosine, and/or other adenosine compounds.